Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension | Zendy

Nazzareno Galiè | Zendy; Joan Albert Barberà | Zendy; Adaani Frost | Zendy; Hossein A. Ghofrani | Zendy; Marius M. Hoeper | Zendy; Vallerie V. McLaughlin | Zendy; Andrew J. Peacock | Zendy; Gérald Simonneau | Zendy; JeanLuc Vachiéry | Zendy; Ekkehard Grünig | Zendy; Ronald J. Oudiz | Zendy; Anton Vonk Noordegraaf | Zendy; R. James White | Zendy; Christiana Blair | Zendy; Hunter Gillies | Zendy; Karen Miller | Zendy; Julia Harris | Zendy; Jonathan Langley | Zendy; Lewis J. Rubin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

Author(s) -

Nazzareno Galiè,

Joan Albert Barberà,

Adaani Frost,

Hossein A. Ghofrani,

Marius M. Hoeper,

Vallerie V. McLaughlin,

Andrew J. Peacock,

Gérald Simonneau,

JeanLuc Vachiéry,

Ekkehard Grünig,

Ronald J. Oudiz,

Anton Vonk Noordegraaf,

R. James White,

Christiana Blair,

Hunter Gillies,

Karen Miller,

Julia Harris,

Jonathan Langley,

Lewis J. Rubin

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1413687

Subject(s) - ambrisentan , tadalafil , medicine , combination therapy , clinical endpoint , pulmonary hypertension , placebo , hazard ratio , confidence interval , cardiology , randomized controlled trial , bosentan , erectile dysfunction , endothelin receptor , receptor , alternative medicine , pathology

Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research